Whitepaper · May 2026 · CMC & Quality Executive Search
The CTO Mandate Framework.
A board governance framework for evaluating CMC, Manufacturing & Quality (CMCQ) leadership in biopharma. Eight years to write, drawing on 120+ commercial product launches — the collective careers of seventeen CxO-level technical operations leaders who have led CMCQ at world-leading Fortune 100, mid-cap, and startup biotech. It replaces the question "is the CTO good?" with the more precise one: "is our CMC leadership calibrated to the risk most likely to end our next capital event?"
Already downloaded by 300+ CMC, Quality & Tech Ops leaders across 200+ biopharma companies.
Why It Matters
Manufacturing and quality risk is no longer a technical footnote. It is a board-level valuation issue.
Technical risk in biopharma rarely announces itself early. It is repriced later — by the FDA, an acquirer, the IPO market, or the next financing round. This framework helps boards identify and govern that risk before the capital event does.
62.6%
of the FDA’s 457 published Complete Response Letters carry a manufacturing or quality deficiency section (Phase 3 Search, July 2026), the leading cause, and lower than the widely quoted 74%
1.28 yrs
median CRL-to-approval delay for novel therapeutics (Dilek et al., 2026)
33% vs 75%
single-day valuation decline — preventable manufacturing CRL vs clinical failure
6.7%
probability of reaching approval from Phase I, across 10,954 programs (2014–2023)
Across 10,954 drug development programs (2014–2023), the probability of reaching approval from Phase I has declined to roughly 6.7%. As clinical probabilities tighten, operational execution becomes a larger determinant of enterprise value — and boards systematically misprice it.
The most commonly cited approval-blocking deficiencies are not clinical. They are manufacturing and CMC. A Jefferies analysis, reported by BioSpace in May 2026, found that across the FDA's now-public CRL repository of more than 200 letters, more than half cite manufacturing and 41% cite product quality, and manufacturing has been the most common CRL cause for years. (CRLs are typically multi-causal; this is the share that cite quality or manufacturing as a factor.)
A preventable manufacturing CRL has triggered single-day valuation declines in the 33–34% range. The difference from a clinical failure is decisive: manufacturing CRLs sit within the CTO's mandate. They are preventable with the right governance.
Could your CTO prevent a manufacturing CRL — or would you find out at filing?
FDA Complete Response Letters · cited deficiency
Cite manufacturing50%+
Cite product quality41%
Insufficient clinical data27%
Jefferies analysis (Andrew Tsai), reported by BioSpace, 2026, corroborated by Mizuho's Graig Suvannavejh (analysis of the FDA's CRL repository, more than 200 letters published since 2025); also corroborated by Pharmaceutical Technology and Pharma Manufacturing. The dominant approval-blocking deficiencies sit inside the CTO's mandate, and they are preventable.
The Evidence
Manufacturing vs. clinical failures.
Manufacturing CRLs triggered 33–34% single-day valuation declines. Clinical failures triggered 50–75%. The difference: manufacturing CRLs sit within the CTO's mandate. They are preventable with the right governance.
The companies below are illustrative examples, not a statistical distribution. The load-bearing evidence is the population-level finding above: 62.6% of the FDA's 457 published CRLs carry a manufacturing or quality deficiency section (Phase 3 Search, July 2026), lower than the widely quoted 74% and still the leading cause; Jefferies' read of the same archive found more than half cite manufacturing and 41% product quality.
| Company | Year | Valuation impact | CRL type |
|---|---|---|---|
| Fortress Biotech | 2025 | −33.7% | CMC / Mfg |
| Alvotech | 2025–26 | −34% | CMC / Mfg |
| Immunomedics | 2019–20 | Delayed | CMC / Mfg |
| Applied Therapeutics | 2024 | −75% | Clinical |
| Corcept Therapeutics | 2025 | −50% | Clinical |
How It Works
Five mandates. Emphasis shifts by stage.
CMC performance is not fixed "technical strength." It is a stage-specific risk function with five simultaneous dimensions. At any given stage, one mandate is dominant — its failure is most likely to be fatal to the current capital event — but the others remain active. The correct mental model is a radar chart, not a checklist.
Dominant emphasis at
Pre-IND
At each stage one mandate dominates — the failure most likely to end the current capital event — while the others stay active. Watch the shape rotate from Possible (pre-IND) through to Durable (commercial). The right hire is calibrated to the dominant mandate now, and ready for the one next.
i.
Possible
Make a product possible. Translation into an investable, regulator-legible development position.
Dominant: Pre-IND
ii.
Reproducible
Make it reproducible. Systems replace heroics. CMC, assay, and process control are institutionalized.
Dominant: Phase I–II
iii.
Acquirable
Make it diligence-survivable. Documentation integrity, auditability, and narrative stability under scrutiny.
Dominant: Pre-filing
iv.
Scalable
Build the operational machine. The platform becomes a multi-program operating system.
Dominant: Multi-program
v.
Durable
Harden enterprise performance under stress. Inspections, shortages, geopolitics, redundancy.
Dominant: Commercial
These weightings are directional, not predictive — the CTO Mandate Framework is a practitioner-consensus model, built and pressure-tested by senior operators rather than peer-reviewed research. The value lies in the conversation they structure. The full framework maps dominant, rising, and maintenance mandates across all five stages, with a board calibration tool that surfaces where directors disagree about what the role requires. The framework is also the assessment instrument behind our biotech CTO executive search practice.
Who You Need, By Stage
CTO vs. Head of Tech Ops vs. VP Quality.
Three roles boards routinely conflate. They own different risks — and each is the priority hire at a different moment.
| Title | What they own | The risk they retire | Priority hire when… |
|---|---|---|---|
| Chief Technology Officer (CTO) | Whole CMC and technical strategy across the lifecycle | The therapy cannot be made, scaled, or defended to a regulator | Series A in cell & gene therapy; Series B+ / Phase 2a in other modalities — through pre-IPO calibration and M&A readiness |
| VP/SVP Technical Operations | Converting R&D process to product, CDMO selection, day-to-day manufacturing, tech transfer, and supply | A process that will not reproduce at commercial volume | Series A, through clinical-to-commercial supply; succeeded by a CTO approaching launch or multi-asset build-out |
| VP Quality / CQO | Quality systems, compliance, and inspection readiness | A quality system that buckles at inspection or at scale | Series B / Phase 2 — ahead of pre-approval inspection, or after a quality signal |
Cell & gene therapy is CMC-intensive from the outset — these companies typically need a CTO by Series A, where other modalities can begin with a VP/SVP Technical Operations at Series A and elevate to a CTO at Series B, or as they approach launch or build out a multi-asset portfolio.
How Boards Use It
Two paths to closing the governance gap.
2–4 yrs
time-to-market saved by avoiding a CRL
33–34%
manufacturing CRL valuation loss — preventable
Fewer
CVR concessions in diligence-ready deals
1 hire
the cost of closing the governance gap
Path 1
CMC or manufacturing experience on the board
A voting director with hands-on CMC operating experience — not a scientific advisor. A fiduciary who has managed CAPA systems, led pre-approval inspections, and negotiated CMC deficiency responses with the FDA, and who can distinguish a manageable deviation trend from a systemic quality-culture failure in real time.
Path 2
A CTO who educates up and provides clarity
If you do not have a CMC board member, you need a CTO who can translate operational risk into language directors and investors understand — and create an unfiltered information channel so the board learns about manufacturing risk before it becomes a CRL. The most undervalued CTO capability in biopharma.
Three of five deflection-resistant board questions
- 1What is the current deviation / CAPA aging backlog — and the trend over the last three quarters?
- 2How many critical processes depend on a single individual? What is our bus factor?
- 3If an acquirer’s diligence team arrived tomorrow, what would they find?
The one question every board should ask
Does your CTO have the authority that matches your dominant mandate?
The Reception
Downloaded by leaders at the forefront of building medicine.
Downloaded by 300+ senior CMC, Quality and Technical Operations leaders — CxOs, VPs and function heads — across 200+ biopharma companies, and read at board and investor level.
320+
downloads
200+
companies
90+
CxOs (incl. consultants)
100+
VPs & function heads
A representative sample of organizations whose teams downloaded the framework. We never share individual details.
The Team Behind the Paper
Reviewed and pressure-tested.
Shaped by the collective careers of seventeen CxO-level technical operations leaders who have run CMC, Manufacturing and Quality at world-leading Fortune 100, mid-cap, and startup biotech — more than 120 commercial product launches and over 500 collective years running CMC, Manufacturing and Quality between them. This is not one operator's opinion; it is the institutional memory of the people who have actually shipped medicine, organized into a single governance model.
500+
years of collective CMC, Tech Ops & Quality leadership
120+
commercial products launched by the panel
112+
CMC and Quality placements by Phase 3 over 13 years
29
page governance framework
Meet the consortium
The seventeen operators who reviewed and pressure-tested the framework — seven hold PhDs. Each links to LinkedIn.
Patrick Y. YangFormer EVP, Technical Operationsin →Joanne Tzouvalopoulos BeckChief Operating Officer & Board Directorin →Timothy MainesChief Technical Operations & Quality Officerin →Susan Abu-AbsiChief Operating Officer / CTOin →John StubenrauchChief Technology Officerin →Hari PujarChief Operating Officerin →Nur NicholsonChief Technical Operations Officerin →Sean HemingwayChief Operating Officerin →Jay StoutChief Technology Officerin →Boyd SpencerChief Transformation Officer (ex-McKinsey Partner)in →Ian B. WilcoxManaging Partnerin →Peter ThompsonSVP, Technical Operationsin →Bryan GillisFormer Chief Technical Officerin →José Manuel (Manny) OteroChief Operating Officerin →Kyle HaraldsenChief Technical Operations Officerin →Daniel CoutoChief Operating Officerin →Aaron VernonChief Technology Officerin →
Download
Get the full 29-page framework.
The complete governance matrix, the Board Calibration Tool, and the operational KPI sets.
Frequently Asked Questions
Asked, answered.
What is the CTO Mandate Framework? +
A 29-page governance framework that gives boards a structured way to evaluate whether their CTO's priorities are aligned to the company's current stage. It replaces "is the CTO good?" with the more precise "is the CTO's emphasis calibrated to our dominant risk?"
Who should use it? +
Board members evaluating technical leadership. CEOs preparing for capital events (Series B+, crossover, IPO, M&A). Investors conducting CMC diligence. CTOs who want to pressure-test their own emphasis profile against a structured governance model.
How does CMC risk affect biopharma valuation? +
Manufacturing-related CRLs trigger median single-day valuation declines of approximately 34%, with first-time launchers averaging 2.5 years from CRL to approval. The framework includes a financial-impact analysis with company-level data.
What does downloading commit me to? +
Nothing. You receive the full 29-page framework as a PDF. We may send occasional updates on CMC governance and technical leadership, and you can unsubscribe at any time.
What does Phase 3 Search do? +
Phase 3 Search is a life sciences executive search firm specializing in CMC, Quality, and Technical Operations leadership. We built the framework from years of placing these leaders across development-stage and commercial biopharma. See the practice →
CMC & Quality Are Our Disciplines
Apply the framework to your next hire.
If you would like to discuss how this applies to your board, your CTO mandate, or your next technical leadership hire, we welcome the conversation.